MLYS — Mineralys Therapeutics, Inc. Dilution Risk Tracker

Mineralys Therapeutics, Inc. (MLYS) has a DilutionScore of 49/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

Cash runway is a key watch item: MLYS has approximately 12 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for MLYS in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for MLYS alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.